⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12595238 | 0.69 | — | — | |
| SCHEMBL18766887 | 0.67 | — | — | |
| SCHEMBL19772678 | 0.67 | — | — | |
| SCHEMBL17243874 | 0.63 | — | — | |
| SCHEMBL22782154 | 0.63 | — | — | |
| SCHEMBL23154162 | 0.63 | — | — | |
| SCHEMBL24815754 | 0.63 | — | — | |
| SCHEMBL20208570 | 0.63 | — | — | |
| SCHEMBL21026100 | 0.61 | — | — | |
| SCHEMBL24959574 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145053-A1 | TYRAMIDE AND TYRAMIDE ANALOG CONJUGATES AND USES THEREOF FOR BIOLOGICAL TARGET STAINING PROCEDURES | Life Technologies Corporation (US) | 2024-07-04 | — | — | WO | disclosed |
| US-20230190951-A1 | CONJUGATES OF ANTIBODIES AN IMMUNE CELL ENGAGERS | SYNAFFIX B.V. (NL) | 2023-06-22 | — | — | US | disclosed |
| US-11130758-B2 | Tetrahydropyrazolopyrimidine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-09-28 | — | — | US | disclosed |
| US-20200347050-A1 | TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-11-05 | — | — | US | disclosed |
| US-10640500-B2 | Tetrahydropyrazolopyrimidine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-05-05 | — | — | US | disclosed |
| US-9850242-B2 | Tetrahydropyrazolopyrimidine compounds | EISAI R&D MANAGEMENT CO., LTD (JP) | 2017-12-26 | — | — | US | disclosed |
| US-9850242-B2 | Tetrahydropyrazolopyrimidine compounds | EISAI R&D MANAGEMENT CO., LTD (JP) | 2017-12-26 | — | — | US | disclosed |
| US-20160339032-A1 | TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-11-24 | — | — | US | disclosed |
| US-20160339032-A1 | TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-11-24 | — | — | US | disclosed |
| US-9446046-B2 | Tetrahydropyrazolopyrimidine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-9446046-B2 | Tetrahydropyrazolopyrimidine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-20 | — | — | US | disclosed |
| US-20160229918-A1 | TUMOR SELECTIVE ANTIBODIES SPECIFIC TO ONCOFETAL ANTIGEN/IMMATURE LAMININ RECEPTOR PROTEIN | BENOVUS BIO, INC. (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160030430-A1 | TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| US-20160030430-A1 | TETRAHYDROPYRAZOLOPYRIMIDINE COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| WO-2015168466-A1 | INHIBITORS OF LYSINE SPECIFIC DEMETHYLASE-1 | Quanticel Pharmaceuticals, Inc. (US) | 2015-11-05 | — | — | WO | disclosed |
| US-9126999-B2 | Tetrahydropyrazolopyrimidine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-09-08 | — | — | US | disclosed |
| US-9126999-B2 | Tetrahydropyrazolopyrimidine compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-09-08 | — | — | US | disclosed |
| WO-2015058160-A1 | BROMODOMAIN INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2014100695-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2014-06-26 | — | — | WO | disclosed |
| WO-2011072207-A1 | AZOCYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-06-16 | — | — | WO | disclosed |